BioPharmSignal logoBioPharmSignal

Biotech News

Assembly Biosciences Announces Pricing of $175 Million in Equity Financings

Assembly Biosciences (ASMB)Assembly BiosciencesFinancing

SOUTH SAN FRANCISCO, Calif., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (“Assembly Bio”) (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, today announced the pricing of an underwritten, registered offering (the

Open original release

Related news

ASMBAssembly Biosciences2026-05-22 11:05 EST

Assembly Biosciences Announces Pricing of $100 Million Offering of Common Stock and Pre-Funded Warrants

ASMBAssembly Biosciences2026-05-26 20:05 EST

Assembly Biosciences Announces the Closing of its Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

OGENOragenics2025-07-01 12:31 EST

Oragenics, Inc. Announces Pricing of Public Offering of up to $20 Million of Preferred Stock and Warrants

ANTXAN2 Therapeutics2026-03-09 11:00 EST

AN2 Therapeutics Announces $40 Million Private Placement Financing

OGENOragenics2025-07-02 20:15 EST

Oragenics Completes Approximately $16.5 Million Offering

SPROSpero Therapeutics2026-07-14 11:02 EST

Spero Therapeutics Announces $105 Million Non-Recourse Non-Dilutive Financing Backed by a Portion of Utebzi Milestones & Royalties

VIRIVirios Therapeutics2026-01-12 13:30 EST

Dogwood Therapeutics, Inc. Announces Financing of up to $26.8 Million to Progress Halneuron® Through Phase 2b Development

SCYXSCYNEXIS2026-03-31 10:45 EST

SCYNEXIS Announces $40.0 Million Private Placement

SPROSpero Therapeutics2023-11-01 08:05 EST

Spero Therapeutics Appoints Esther Rajavelu as Chief Financial Officer and Chief Business Officer

View all latest news

Assembly Biosciences

Assembly Biosciences is a biotechnology company focused on antiviral disease biology and microbiome-related discovery. Its story is built around trying to translate targeted biology into therapies for difficult infectious diseases.

Recent company news

ASMBAssembly Biosciences2026-05-28 20:05 EST

Assembly Biosciences Announces Upcoming Investor Conference Presentations

ASMBAssembly Biosciences2026-05-26 20:05 EST

Assembly Biosciences Announces the Closing of its Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

ASMBAssembly Biosciences2026-05-22 11:05 EST

Assembly Biosciences Announces Pricing of $100 Million Offering of Common Stock and Pre-Funded Warrants

ASMBAssembly Biosciences2026-05-22 11:00 EST

Assembly Biosciences Announces Expansion of ABI-6250 Clinical Development Into Cholestatic Liver Diseases

ASMBAssembly Biosciences2026-05-13 06:00 EST

Assembly Biosciences to Present Topline Phase 1a Data on Hepatitis Delta Virus Entry Inhibitor ABI-6250 at the EASL Congress 2026

Stock data

Close
25.91 USD
Market cap
485.32M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States